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Abstract
Novel	therapies	such	as	type	2	targeting	biologics	are	emerging	treatment	options	
for	 patients	with	 chronic	 inflammatory	 respiratory	 diseases,	 fulfilling	 the	 needs	 of	
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1  | INTRODUC TION
Chronic	 rhinosinusitis	 (CRS)	 is	 a	 chronic	 inflammatory	 condition	 of	
the	sinonasal	cavities	that	affects	5%-12%	of	the	general	population	
worldwide	 according	 to	 epidemiological	 studies.1-4	 The	 European	
Position	 Paper	 on	 Rhinosinusitis	 and	 Nasal	 Polyps	 (EPOS)	 defines	
CRS	clinically	based	on	symptoms	supported	by	signs	of	mucosal	in-
flammation	found	on	imaging	or	with	nasal	endoscopy.5	Recently,	the	
prevalence	of	clinically	based	CRS	has	shown	to	be	between	3%	and	
6.4%.6,7	CRS	is	classically	divided	into	a	phenotype	with	and	without	
nasal	polyps	(CRSwNP	and	CRSsNP,	respectively).	Using	patient	ques-
tionnaires	to	measure	the	prevalence	of	CRSwNP	yielded	estimates	of	
2.1%	(France)	to	4.3%	(Finland)	in	Europe	and	1.1%	in	China.8	CRSwNP	
comprises	a	heterogeneous	group	of	patients	who	differ	with	respect	
to	coexisting	asthma,	allergy,	NSAID-exacerbated	respiratory	disease	
(N-ERD),9	 smoking,	 age	 of	 onset,	 and	 disease	 severity.10-12	 Asthma	
affects	 30%-70%	 of	 the	 CRSwNP	 patients.8,10,13,14	 Conversely,	 the	
presence	of	nasal	polyps	is	associated	with	the	severity	of	asthma,	re-
gardless	of	smoking	status	ranging	from	10%-30%	in	mild	asthma	to	
70%-90%	in	severe	asthma.15,16	Both	CRSwNP	and	asthma	share	com-
mon	 underlying	 pathophysiological	mechanisms	 driving	 the	 disease	
(endotype),	of	which	type	2	inflammation	is	the	most	prominent.13,17-19 
Type	2	inflammation	is	characterized	by	the	presence	of	eosinophilic	
airway	inflammation	associated	with	type	2-related	cytokines	(IL4,	IL5,	
and/or	IL13)	and	circulating	and/or	local	IgE.13,20
The	 management	 guideline	 in	 Europe	 for	 CRS,	 the	 European	
Position	Paper	on	Rhinosinusitis	and	Nasal	Polyps	(EPOS),	has	been	
developed	to	provide	physicians	with	comprehensive	tables	of	lev-
els	of	evidence	and	helpful	management	algorithms.5	In	the	United	
States,	 similar	consensus	statements	have	been	published	 in	2016	
by	Orlandi	et	al.21
The	 cornerstone	 of	 the	 management	 of	 both	 CRSwNP	 and	
asthma	 consists	 of	 anti-inflammatory	 treatment	 with	 local	 corti-
costeroids,	aiming	to	achieve	optimal	disease	control.5,21,22	When	
this	 is	 insufficient,	 short	 courses	of	oral	 corticosteroids	 are	used	
(usually	30-60	mg	for	14	days,	sometimes	reducing	over	time).23,24 
Sinus	surgery	is	the	treatment	option	for	CRSwNP	patients	in	cases	
failing	 medical	 treatment.25-27	 Recently,	 also	 more	 attention	 has	
been	paid	to	the	concept	of	“treatable	traits.”	Treatable	traits	have	
been	postulated	as	a	management	concept	which	complements	the	
traditional	diagnostic	 labels	such	as	CRSwNP	or	CRSsNP,	thereby	
focusing	on	 therapy	 targeted	 to	a	patient's	 individual	disease-as-
sociated	 characteristics.28,29	 Typical	 treatable	 traits	 in	 the	 upper	
airways	can	be	smoking,	allergy,	occupation,	and	mucociliary	clear-
ance	deficits.30
Biological	therapies	have	entered	the	market	for	patients	with	
asthma	almost	15	years	ago	with	anti-IgE	as	first-line	therapy	for	
patients	with	severe	allergic	asthma	31	and	urticaria.32-35	Recently,	
other	 monoclonal	 antibodies	 targeting	 type	 2	 inflammation	 36 
have	been	approved	and	are	available	now	for	patients	with	eo-
sinophilic	asthma,37-41	atopic	dermatitis,42,43	and	urticaria.36,42-46 
A	number	 of	 trials	 have	been	done	with	 biological	 therapies	 for	
CRSwNP.47-50	As	these	drugs	enter	the	market,	it	necessitates	the	
medical	community	to	reflect	on	the	positioning	of	these	therapies	
in	the	current	care	pathways	of	the	upper	and	lower	airways.51,52
The	 European	 Forum	 for	 Research	 and	 Education	 in	 Allergy	
and	 Airway	 Diseases	 organized	 a	 multidisciplinary	 Expert	 Board	
Meeting	on	November	29-30,	2018,	to	develop	proposals	for	the	
positioning	 of	 biologics	 into	 the	 care	 pathways	 for	 CRSwNP	 pa-
tients	 with	 or	 without	 asthma.	 Subsequently,	 a	 patient	 advisory	
board	 meeting	 was	 held	 to	 discuss	 the	 outcomes	 of	 the	 Expert	
Board	Meeting.
severely	uncontrolled	patients.	The	majority	of	patients	with	chronic	 rhinosinusitis	
with	nasal	 polyps	 (CRSwNP)	 and	over	half	 of	patients	with	 asthma	 show	a	 type	2	
inflammatory	signature	in	sinonasal	mucosa	and/or	lungs.	Importantly,	both	chronic	
respiratory	diseases	are	 frequent	comorbidities,	 ensuring	alleviation	of	both	upper	
and	lower	airway	pathology	by	systemic	biological	therapy.	Type	2-targeting	biologics	
such	as	anti-IgE,	anti-IL4Rα,	anti-IL5,	and	anti-IL5Rα	have	entered	the	market	for	se-
lected	pheno/endotypes	of	asthma	patients	and	may	soon	also	become	available	for	
CRSwNP	patients.	Given	the	high	prevalence	of	chronic	respiratory	diseases	and	the	
high	cost	associated	with	biologics,	patient	selection	is	crucial	in	order	to	implement	
such	therapies	into	chronic	respiratory	disease	care	pathways.
The	European	Forum	for	Research	and	Education	in	Allergy	and	Airway	Diseases	
(EUFOREA)	organized	a	multidisciplinary	Expert	Board	Meeting	to	discuss	the	posi-
tioning	of	biologics	 into	the	care	pathways	for	CRSwNP	patients	with	and	without	
comorbid	asthma.
K E Y W O R D S
asthma,	biologics,	chronic	rhinosinusitis,	nasal	polyps,	type	2	inflammation
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2  | SE VERIT Y AND THE BURDEN OF 
UNCONTROLLED DISE A SE IN CRSwNP AND 
A STHMA
CRSwNP	has	a	severe	impact	on	quality	of	life	comparable	to	asthma	
53,54	and	poses	a	significant	burden	on	society.54,55	In	particular,	the	
loss	of	 sense	of	 smell	 is	a	debilitating	and	often	underappreciated	
component	and	can	significantly	impact	one’s	quality	of	life.56,57
The	 terms	 “disease	 control”	 and	 “disease	 severity”	 cannot	 be	
used	interchangeably.	In	CRSwNP,	severity	is	defined	by	the	impact	
of	the	symptoms	on	general	quality	of	life	and	it	can	be	measured	
with	 VAS	 and/or	 SNOT-22.58	 Uncontrolled	 disease	 in	 CRS	 is	 de-
fined	as	persistent	symptoms	such	as	nasal	blockage,	mucopurulent	
rhinorrhea/postnasal	drip,	facial	pain/headache,	impaired	sense	of	
smell	or	sleep	disturbance/fatigue,	and/or	diseased	mucosa	in	the	
last	3	months	or	the	need	for	long-term	antibiotics	or	systemic	ste-
roids	 in	 the	 last	month.5,58,59	Few	real-life	studies	have	evaluated	
the	burden	of	uncontrolled	disease	following	these	criteria.	A	study	
performed	at	an	academic	referral	center	showed	that	at	least	40%	
of	CRS	patients	are	uncontrolled	despite	maximal	medical	and	sur-
gical	treatment	60.
The	goal	of	CRS	management	is	to	achieve	and	maintain	clinical	
control	with	minimal	use	of	medication	and	associated	side	effects	
or	surgical	interventions.	Additionally,	the	frequency	of	recurrence	
of	nasal	polyps	and	the	need	for	systemic	corticosteroids	might	be	
measures	 of	 disease	 control.	 In	 clinical	 practice,	 systemic	 cortico-
steroids	are	used	more	frequently	and	for	longer	periods	than	pro-
posed	in	guidelines.8,60	Real-life	studies	are	needed	to	determine	the	
cumulative	 exposure	 to	 corticosteroids	 of	 patients	with	 comorbid	
CRSwNP	and	asthma.	The	side	effects	of	repeated	use	of	systemic	
corticosteroids	were	also	identified	by	the	patient	advisory	board	as	
a major concern.61
Symptomatic	 nasal	 polyp	 recurrence	 rates,	 defined	 as	patients	
undergoing	 revision	 endoscopic	 sinus	 surgery,	 are	 reported	 to	 be	
20%	within	a	5-year	period	after	surgery	62,63	but	may	be	as	high	as	
50%	on	endoscopic	examination.62
Type	 2	 disease	 is	 a	 strong	 predictor	 of	 recurrent	 disease	with	
more	 than	 50%	 of	 recurrences	 occurring	 in	 clusters	 with	 high	
eosinophilia.62-65
The	 Global	 Initiative	 for	 Asthma	 (GINA)	 suggests	 assessing	
asthma	severity	retrospectively	from	the	level	of	treatment	required	
to	control	symptoms	and	exacerbations.	Mild	asthma	is	asthma	that	
can	 be	 controlled	 with	 low-dose	 inhaled	 corticosteroids.	 Severe	
asthma	 is	 defined	 as	 asthma	 that	 requires	 treatment	 with	 high-
dose	 inhaled	 corticosteroids	 (ICS)	 plus	 a	 second	 controller	 and/or	
systemic	 corticosteroids	 to	maintain	 symptom	control	 (after	other	
causes	of	 lack	of	control,	 that	 is,	 treatment	adherence	and	 inhala-
tion	technique	have	been	addressed)	or	asthma	that	remains	uncon-
trolled	despite	this	(maximal)	therapy.66
There	is	a	clear	correlation	between	control	of	upper	and	lower	
airways	 in	 patients	with	CRS	 and	 asthma	 and	many	 patients	with	
severe	asthma	have	comorbid	CRSwNP,	which	should	be	addressed	
to	 optimize	 asthma	 control.67-69	 To	 conclude,	 the	management	 of	
CRSwNP	and	 asthma	patients	who	are	uncontrolled	despite	med-
ical	 and	often	 surgical	 intervention	 remains	a	 challenge.	However,	
in	 recent	 years,	 there	 has	 been	 significant	 innovation	 and	 expan-
sion	in	the	treatment	armamentarium	since	the	advent	of	biological	
therapies.
3  | EFFIC ACY OF BIOLOGIC AL 
TRE ATMENT FOR CRSwNP AND A STHMA
Omalizumab	was	the	first	biological	therapy	that	entered	the	market	
for	patients	with	moderate-to-severe	allergic	asthma.	 It	have	been	
shown	to	improve	disease	control,	reduce	the	number	of	asthma	ex-
acerbations,	the	need	for	oral	corticosteroid,	and	rescue	medication	
use.31,70	In	recent	years,	several	other	biologics	(anti-IL5,	anti-IL5R,	
and	anti-IL4Rα)	have	shown	to	be	effective	for	the	treatment	of	se-
vere	asthmatics	with	a	type	2	 inflammatory	signature.71,72	 In	most	
countries,	 biologics	 are	 indicated	 in	 moderate-to-severe	 asthma	
with	insufficient	level	of	control	despite	high	dose	of	inhaled	corti-
costeroids	combined	with	at	least	one	other	asthma	medication	and	
where	 severe	 exacerbations	 and/or	 oral	 corticosteroid-dependent	
asthma	have	been	demonstrated.
The	 first	 proof-of-concept	 studies	 in	 CRSwNP	 using	 anti-IgE,	
anti-IL5,	 and	 anti-IL4Rα	 strategies	 also	 showed	 promising	 results	
and	have	been	 summarized	earlier.50,73	Recent	 larger	 scale	 studies	
showed	 a	 moderate	 reduction	 in	 the	 need	 for	 surgery	 following	
treatment	with	anti-IL5	in	patients	with	CRSwNP.48	It	was	stated	ear-
lier	that	asthma	is	a	frequent	comorbidity	in	patients	with	CRSwNP.	
All	trials	with	biologics	in	CRSwNP	also	showed	a	positive	impact	on	
the	lower	airways	with	significant	changes	in	either	AQLQ,	ACQ-5,	or	
FEV1 in	patients	with	comorbid	asthma.
47,48,74	Each	of	these	biologics	
is	tested	in	phase	III	clinical	trials	for	CRSwNP	patients	with	results	to	
F I G U R E  1   Indications	for	biological	treatment	in	patients	with	
CRSwNP:	proposal	of	the	multidisciplinary	EUFOREA	Expert	Board	
Meeting
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be	expected	in	2019.	Preliminary	data	suggest	a	significant	positive	
impact	on	quality	of	life,	especially	on	the	sense	of	smell	and	reduc-
tion	in	the	need	for	surgery	and	systemic	corticosteroid	treatment.
4  | INDIC ATIONS FOR BIOLOGIC S
The	 high	 burden	 of	 uncontrolled	 disease,	 the	 recurrence	 of	 nasal	
polyps	 after	 sinus	 surgery,	 and	 the	 side	 effects	 associated	 with	
repeated	courses	of	oral	corticosteroids	all	underline	the	need	for	
novel	therapies.	Given	that	biologics	come	with	a	high	cost	for	the	
healthcare	 system,	 careful	 selection	 of	 patients	 is	 highly	 recom-
mended.	The	EUFOREA	expert	 team	has	put	 forward	 five	 criteria	
that	are	important	in	the	decision	to	prescribe	biologics	in	CRSwNP	
with	prior	sinus	surgery	(Figure	1):
Evidence	of	type	2	inflammation	(biological	biomarker)
Need	for	systemic	corticosteroids	in	the	past	2	years
Significant	quality-of-life	impairment
Significant	loss	of	smell
Diagnosis	of	comorbid	asthma
It	was	concluded	that	biologics	are	indicated	in	patients	with	bi-
lateral	nasal	polyps	who	had	undergone	sinus	surgery	in	the	past	and	
meet	3	of	the	above	criteria.
There	was	an	extensive	discussion	of	whether	 there	 is	a	 role	
for	biologics	 in	patients	without	previous	 sinus	 surgery.	 If	 these	
patients	 meet	 the	 criteria	 for	 severe	 asthma,	 they	 might	 ful-
fill	 the	 eligibility	 criteria	 to	 receive	biological	 treatment	 by	 their	
pulmonologist.
In	 patients	 with	 severe	 CRSwNP	 and	 mild-moderate	 asthma,	
the	question	as	 to	whether	biologics	may	become	a	valid	alterna-
tive	for	sinus	surgery	is	difficult	to	answer	before	the	approval	and	
introduction	of	biologics	 into	the	market.	While	most	patients	are	
keen	to	avoid	surgery	 if	possible,	 the	effectiveness	of	biologics	 in	
preventing	or	reducing	the	need	for	surgery	is	yet	to	be	established.	
The	current	evidence	shows	a	significant	but	incomplete,	relatively	
modest,	reduction	in	polyp	size,	suggesting	that	a	notable	propor-
tion	of	patients	might	still	need	surgery	despite	treatment	with	bio-
logics.37-39	On	the	other	hand,	given	that	repeated	surgeries	cannot	
prevent	recurrence	in	CRSwNP	subjects	with	type	2	inflammation,	
and	 in	 line	with	 the	principles	of	precision	medicine	 that	patients	
also	will	share	in	decision	making,	it	is	likely	that	biologics	will	in	time	
become	an	alternative	for	sinus	surgery	as	currently	performed.
To	date,	one	study	evaluated	omalizumab	vs	sinus	surgery	in	pa-
tients	with	grade	3	CRSwNP	and	asthma.49	 It	was	 concluded	 that	
omalizumab	 is	equally	effective	 in	 reducing	SNOT-22	at	16	weeks	
to	sinus	surgery.	However,	large-scale	studies	are	needed	to	confirm	
these	findings	in	order	to	decide	upon	whether	or	not	biologics	could	
be	a	valid	alternative	to	primary	sinus	surgery.
Therefore,	 it	was	concluded	 that	patients	who	have	never	had	
sinus	surgery	need	to	meet	at	least	4	of	the	above	criteria	in	order	to	
be	eligible	for	biological	treatment.
Finally,	 indications	 not	 to	 initiate	 type	 2	 biological	 treatment	
were	defined	as	follows:
CRSsNP	and	lack	of	signs	of	type	2	inflammation
Cystic	fibrosis
Unilateral	nasal	polyps
Mucoceles
General	 contraindications	 for	 biological	 treatments,	 such	 as	
immunodeficiencies
Patient-related	factors	such	as	noncompliance	to	therapy
5  | DEFINING RESPONSE TO BIOLOGIC S
Despite	significant	efficacy	of	biologics	on	various	clinical	and	pa-
tient-reported	 outcome	measures	 in	 the	 overall	 study	 population,	
F I G U R E  2  Response	criteria	for	
biological	treatment	in	patients	with	
CRSwNP:	proposal	of	the	multidisciplinary	
EUFOREA	Expert	Board	Meeting
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considerable	variability	in	the	degree	of	response	to	such	therapies	
is	seen.	These	observations	underpin	the	need	to	identify	treatment	
responders	 as	well	 as	 nonresponders.	 The	 following	 criteria	were	
agreed	by	the	expert	team	to	define	response	to	biological	therapy	
after	1	year	(Figure	2):
Reduced	nasal	polyp	size
Reduced	need	for	systemic	corticosteroids
Improved	quality	of	life
Improved	sense	of	smell
Reduced	impact	of	comorbidities
Three	categories	of	response	were	defined	as	follows:	poor	(1-2	
criteria),	good	(3-4	criteria),	or	excellent	(5	criteria).	It	was	proposed	
to	assess	the	response	to	treatment	after	16	weeks	in	order	to	de-
cide	upon	continuation	of	 the	 treatment	 (early	 stopping	 rule).	The	
group	felt	that,	ethically	and	clinically,	an	assessment	point	was	re-
quired	to	avoid	unnecessary	continuation	of	a	treatment	which	was	
not	working	and	had	chosen	16	weeks	after	discussion,	but	recog-
nize	 that	 this	will	be	validated/may	change	when	 further	 informa-
tion	becomes	available	from	ongoing	trials.	It	should	be	noted	that	
real-life	studies	are	currently	 lacking	to	confirm	the	16-week	early	
stopping	time	point.
6  | POSITIONING OF BIOLOGIC S IN 
THE CHRONIC RESPIR ATORY DISE A SE‐
INTEGR ATED C ARE PATHWAY
New	 developments	 in	 understanding	 pathophysiology	 and	 treat-
ment	 require	 new	 care	 pathways.	 Recently,	 integrated	 care	 path-
ways	 incorporating	 the	 different	 phenotypes	 and	 endotypes	 have	
been	proposed.75,76	Although,	as	we	speak,	biologics	do	not	yet	have	
an	indication	for	CRSwNP,	we	can	expect	this	to	happen	in	the	very	
near	future.
Implementing	integrated	care	pathways	into	daily	clinical	prac-
tice	 requires	both	collaboration	between	 first,	 second,	and	 third	
lines	 of	 care	 and	 across	 specialties	 (ENT,	 pulmonology,	 allergol-
ogy).	Patients	pointed	out	during	the	advisory	board	meeting	that	
awareness	about	CRS	and	nasal	polyps	and	best-practice	manage-
ment	options	are	unsatisfactory.	Thus,	 it	 is	 the	patients’	percep-
tion	that	timely	referral	to	a	specialist	is	often	delayed.	Education	
of	both	patients	and	primary	care	physicians	 is	 thought	to	facili-
tate	timely	and	accurate	diagnosis	of	patients	with	CRSwNP	and/
or	asthma.	Because	there	are	 indications	that	early	treatment	of	
CRS	may	prevent	asthma	and	further	healthcare	use,77	appropri-
ate	management	at	the	right	level	of	care	may	eventually	prevent	
further	 development	 of	 disease	 and	 be	 highly	 cost-effective.	
Patients	with	 a	high-risk	phenotype	 (asthma	and	N-ERD)	 should	
be	referred	to	specialist	centers	early	in	their	disease	to	optimize	
multidisciplinary	management.
Many	 patients	will	 predominantly	 have	 upper	 or	 lower	 airway	
diseases.	However,	it	is	recommended	that	every	patient	with	CRS	
gets	at	least	one	systematic	evaluation	for	asthma	and	allergy	pref-
erably	 by	 a	 validated	 questionnaire	 and	 if	 at	 risk	 for	 asthma,	 spi-
rometry	to	assess	lung	function;	skin	prick	test	or	measurement	of	
specific	 blood	 IgE;	 and	 measurement	 of	 blood	 eosinophil	 counts.	
Similarly,	for	patients	with	asthma	it	is	recommended	that	every	pa-
tient	 is	 evaluated	 for	 upper	 airway	 problems	 (rhinitis	 or	 CRS)	 and	
allergy	 preferably	 by	 a	 validated	 questionnaire;	 nasal	 endoscopy,	
skin	prick	test,	or	measurement	of	specific	blood	IgE;	and	measure-
ment	of	blood	eosinophil	counts.	However,	a	subgroup	of	patients	
with	 severe	CRS	 and	 asthma	may	 benefit	 from	 an	 intensified	 col-
laboration	between	ENT	and	pulmonologist	and	where	appropriate	
allergologist.
Remarkably,	 only	 a	 few	 of	 the	 physicians	 in	 the	 Expert	 Board	
admitted	 to	 having	 a	 multidisciplinary	 outpatient	 clinic	 in	 place.	
Notwithstanding	this,	recommendations	of	the	Board	 included	the	
development	of	a	multidisciplinary	integrated	care	pathway	and	sub-
sequent	implementation	in	daily	practice	with	systematic	evaluation	
of	 both	 upper	 and	 lower	 airways	 at	 every	 visit;	 treatment	 adjust-
ments	with	 attention	 to	 the	 full	 unified	 airways;	 regular	measure-
ment	of	type	2	biomarkers;	and	monitoring	of	the	use	of	systemic	
corticosteroids.
7  | CONCLUSION AND UNMET RESE ARCH 
NEEDS
A	 multidisciplinary	 EUFOREA	 Expert	 Board	 Meeting	 and	 patient	
advisory	board	came	together	under	the	auspices	of	the	European	
Forum	for	Research	and	Education	in	Allergy	and	Airway	Diseases.	
The	participants	 formulated	 a	proposal	 for	 the	positioning	of	 bio-
logics	into	the	care	pathways	for	CRSwNP	with	or	without	asthma	
patients.	Criteria	for	and	against	the	use	of	biologics	and	response	
criteria	were	defined	(Figures	1	and	2).
A	series	of	unmet	needs	for	future	research	were	 identified	as	
follows:
Evaluation	of	biological	 treatment	 in	CRSsNP	with	signs	of	 type	2	
inflammation
Biomarker	research	to	identify	responders	to	biological	treatments
Evaluation	of	the	disease-modifying	effect	of	biological	treatments
Evaluation	 of	 required	 duration	 of	 treatment	 and	 discontinuation	
criteria
Protocols	of	long-term	treatment
Interplay	between	biologics	and	sinus	surgery
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